These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

902 related articles for article (PubMed ID: 17364994)

  • 21. Prevention of bleeding and hemorrhagic complications in surgical patients with inherited factor VII deficiency.
    Wiszniewski A; Szczepanik A; Misiak A; Bykowska K; Szopiński P
    Blood Coagul Fibrinolysis; 2015 Apr; 26(3):324-30. PubMed ID: 25688458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comprehensive review of rFVIIa use in a tertiary care pediatric center.
    Heller M; Lau W; Pazmino-Canizares J; Brandão LR; Carcao M
    Pediatr Blood Cancer; 2008 May; 50(5):1013-7. PubMed ID: 17960639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
    Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
    Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial.
    Mayer SA; Brun NC; Broderick J; Davis SM; Diringer MN; Skolnick BE; Steiner T;
    Neurocrit Care; 2006; 4(3):206-14. PubMed ID: 16757825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, observational study to evaluate hemostasis following recombinant activated FVII treatment in patients in Japan with congenital factor VII deficiency.
    Seita I; Kinai E
    Blood Coagul Fibrinolysis; 2023 Jul; 34(5):295-304. PubMed ID: 37395185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder.
    Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K
    Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.
    Martinowitz U; Kenet G; Lubetski A; Luboshitz J; Segal E
    Can J Anaesth; 2002 Dec; 49(10):S15-20. PubMed ID: 12546003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G; Shafer FE; Rojas P; Seremetis S
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful use of recombinant activated FVII and aminocaproic acid in four neonates with life-threatening hemorrhage.
    Grizelj R; Vuković J; Filipović-Grcić B; Sarić D; Luetić T
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):413-5. PubMed ID: 16788319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U; Erhardtsen E
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of factor VII-deficient patients undergoing joint surgeries--preliminary results of locally developed treatment regimen.
    Windyga J; Zbikowski P; Ambroziak P; Baran B; Kotela I; Stefanska-Windyga E
    Haemophilia; 2013 Jan; 19(1):89-93. PubMed ID: 22845882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes.
    MacLaren R; Weber LA; Brake H; Gardner MA; Tanzi M
    Transfusion; 2005 Sep; 45(9):1434-42. PubMed ID: 16131375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry.
    Phillips LE; McLintock C; Pollock W; Gatt S; Popham P; Jankelowitz G; Ogle R; Cameron PA;
    Anesth Analg; 2009 Dec; 109(6):1908-15. PubMed ID: 19923520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential role of recombinant activated factor VII for the treatment of severe bleeding associated with disseminated intravascular coagulation: a systematic review.
    Franchini M; Manzato F; Salvagno GL; Lippi G
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):589-93. PubMed ID: 17890943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII.
    Schulman S; Tjønnfjord GE; Wallensten R; Martinowitz U; Kenet G
    Thromb Haemost; 2005 Dec; 94(6):1177-80. PubMed ID: 16411390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recombinant activated factor VII in the postanesthetic recovery unit: review of 16 cases].
    Etxániz Alvarez A; Pita Zapata E; Rama Maceiras P; Duro Tacón J; Pose Cambeiro P
    Rev Esp Anestesiol Reanim; 2006 Mar; 53(3):159-62. PubMed ID: 16671259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004-2008).
    Nakar C; Cooper DL; DiMichele D
    Haemophilia; 2010 Jul; 16(4):625-31. PubMed ID: 20158526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery.
    Raivio P; Suojaranta-Ylinen R; Kuitunen AH
    Ann Thorac Surg; 2005 Jul; 80(1):66-71. PubMed ID: 15975342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
    Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
    Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
    Young G; Cooper DL; Gut RZ;
    Haemophilia; 2012 Nov; 18(6):990-6. PubMed ID: 22631073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.